Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Jianping Zhang, PhD, Connie L. Erickson-Miller, PhD, Geoffrey Chan, MD, Yan Yan Zhou, PhD

Blood (2015) 126 (23): 4791.

https://doi.org/10.1182/blood.V126.23.4791.4791

Published: 2015

Journal Articles

Partial Splenic Embolization For The Treatment Of Steroid-Resistant Chronic Idiopathic Thrombocytopenic Purpura

Chiaki Nakaseko, MD, PhD, Emi Togasaki, MD, Naomi Shimizu, MD, PhD, Emiko Sakaida, MD, PhD, Masahiro Takeuchi, MD, PhD, Chikako Ohwada, MD, PhD, Yusuke Takeda, MD, PhD, Shio Sakai, MD, PhD, Shokichi Tsukamoto, MD, Takeharu Kawaguchi, MD, PhD, Tomoya Muto, MD, PhD, Tohru Iseki, MD, PhD, Koutaro Yokote, MD, PhD

Blood (2013) 122 (21): 3543.

https://doi.org/10.1182/blood.V122.21.3543.3543

Published: 2013

Journal Articles

Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation

Jane L. Liesveld, MD, Gordon L. Phillips, II, MD, Michael W. Becker, MD, Louis Constine, MD, Jonathan W. Friedberg, MD, Jeffrey Andolina, MD, MS, Laurie Milner, MD, Therese Smudzin, Ollivier Hyrien, PhD, Katie L Dawson, MD, MPH, Yuhchyau Chen, MD, PhD

Blood (2012) 120 (21): 219.

https://doi.org/10.1182/blood.V120.21.219.219

Published: 2012

Journal Articles

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

Huyen Tran, MBBS, MSc, FRACP, FRCPA, Jamie P Nourse, PhD, Rod Lea, PhD, Timothy A. Brighton, FRCPA, FRACP, MB, BS, MS, Andrew Grigg, MBBS, FRACP, FRCPA, Simon McRae, BMedSc, MBBS, FRACP, FRCPA, Daniel Thurley, MA, MB, BCHIR, Dep. pharm. med, MRCP, FFPM, Maher Gandhi, PhD, FRACP, FRCPath, FRCP, John Catalano, MBBS FRACP FRCPA

Blood (2011) 118 (21): 1157.

https://doi.org/10.1182/blood.V118.21.1157.1157

Published: 2011

Journal Articles

The Role of Helicobacter Pylori in Japanese Children with Chronic Idiopathic Thrombocytopenic Purpura

Hisaya Nakadate, M.D., Ph.D., Jun-Ichi Kitazawa, M.D., Ph.D., Yasuo Horikoshi, M.D., Ph.D., Masayuki Nagasawa, M.D., Ph.D., Masue Imaizumi, M.D., Ph.D., Naoaki Kobayashi, M.D., Ph.D., Masao Kobayashi, M.D., Ph.D., Yukihiro Takahashi, M.D., Ph.D., Kohji Fujisawa, M.D., Ph.D., Akira Shirahata, M.D., Ph.D., Fumio Bessho, M.D., Ph.D.

Blood (2011) 118 (21): 4680.

https://doi.org/10.1182/blood.V118.21.4680.4680

Published: 2011

Journal Articles

Inadequately Regulated Adrenal Steroids through HPA Axis In Chronic Idiopathic Thrombocytopenic Purpura

Doyeun Oh, Young Wan Ha, So Young Chong, Soo-Mee Bang, Man Ho Choi, Bong Chul Chung

Blood (2010) 116 (21): 5130.

https://doi.org/10.1182/blood.V116.21.5130.5130

Published: 2010

Journal Articles

Patients Are Willing to Trade off Efficacy, Safety, and Administration Attributes of Chronic Idiopathic Purpura (ITP) Therapy: Results from a Large North American Discrete Choice Study

Kelly M Grotzinger, F. Reed Johnson, A. Brett Hauber, Semra Özdemir, Mohan V Bala

Blood (2008) 112 (11): 669.

https://doi.org/10.1182/blood.V112.11.669.669

Published: 2008

Journal Articles

Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)

Gregory Cheng, Mansoor N Saleh, James B Bussel, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, Nicole L. Stone

Blood (2008) 112 (11): 400.

https://doi.org/10.1182/blood.V112.11.400.400

Published: 2008

Journal Articles

Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study

Mansoor N Saleh, James B Bussel, Gregory Cheng, Balkis Meddeb, Paul M Burgess, Maria E De Obaldia, Nicole L Stone, Manuel Aivado

Blood (2008) 112 (11): 401.

https://doi.org/10.1182/blood.V112.11.401.401

Published: 2008

Journal Articles

Oral Eltrombopag Treatment Reduces the Need for Concomitant Medications in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

Patrick F. Fogarty, James B Bussel, Gregory Cheng, Mansoor N Saleh, Balkis Meddeb, Christine Bailey, Andres Brainsky

Blood (2008) 112 (11): 3424.

https://doi.org/10.1182/blood.V112.11.3424.3424

Published: 2008

Journal Articles

The Influence of Polymorphisms of Interleukin-17F Genes on the Susceptibility and Clinical Significanse of Chronic Idiopathic Thrombocytopenic Purpura.

Takayuki Saitoh, Tetsuhiro Kasamatsu, Akihiko Yokohama, Hiroshi Handa, Norifumi Tsukamoto, Masamitsu Karasawa, Hatsue Ogawara, Yoshihisa Nojima, Hirokazu Murakami, MD

Blood (2008) 112 (11): 3428.

https://doi.org/10.1182/blood.V112.11.3428.3428

Published: 2008

Journal Articles

Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study.

Gregory Cheng, James B Bussel, Mansoor N Saleh, Balkis Meddeb, Maria E De Obaldia, Manuel Aivado, Nicole L Stone

Blood (2008) 112 (11): 3430.

https://doi.org/10.1182/blood.V112.11.3430.3430

Published: 2008

Journal Articles

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

James B Bussel, Bethan Psaila, Mansoor N Saleh, Sandra Vasey, Bhabita Mayer, Nicole L Stone, Michael Arning

Blood (2008) 112 (11): 3431.

https://doi.org/10.1182/blood.V112.11.3431.3431

Published: 2008

Journal Articles

Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura.

James B Bussel, Gregory Cheng, Mansoor N Saleh, Balkis Meddeb, Christine Bailey, Nicole L Stone, Manuel Aivado

Blood (2008) 112 (11): 3432.

https://doi.org/10.1182/blood.V112.11.3432.3432

Published: 2008

Journal Articles

Profiles of Th1, Th2, Th17 and Treg Cells in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

Rong-Fu Zhou, Jian Ou-yang, Da-Yu Chang, Jing-Yan Xu, Bing Chen, Yong-Gong Yang, Qi-Guo Zhang, Xiao-Yan Shao

Blood (2008) 112 (11): 3404.

https://doi.org/10.1182/blood.V112.11.3404.3404

Published: 2008

Journal Articles

Safety of Eltrombopag, an Oral Non-Peptide Platelet Growth Factor, in the Treatment of Thrombocytopenia: Results of Four Randomized, Placebo-Controlled Studies

James B. Bussel, MD, John McHutchison, MD, Drew Provan, MD, A. Jagiello-Gruzfeld, MD, Rezvan Rafi, Sophia Goodison

Blood (2007) 110 (11): 1299.

https://doi.org/10.1182/blood.V110.11.1299.1299

Published: 2007

Journal Articles

Prevalence Estimates of Adult Chronic Idiopathic Thrombocytopenic Purpura (ITP) in the United States.

Maurilee A. Feudjo-Tepie, PhD, Noah J. Robinson, BSc, MSc, PhD, Dimitri Bennett, MD, MPH

Blood (2007) 110 (11): 3202.

https://doi.org/10.1182/blood.V110.11.3202.3202

Published: 2007

Journal Articles

Interleukin-10 Gene Polymorphism Reflects the Severity of Chronic Idiopathic Thrombocytopenic Purpura.

Takayuki Saitoh, MD, Tetsuhiro Kasamatsu, Madoka Inoue, W.H.S. Al-ma’Quol, Akihiko Yokohama, M.D., Hiroshi Handa, M.D., Takafumi Matsushima, M.D., Norifumi Tsukamoto, M.D., Masamitsu Karasawa, M.D., Hatsue Ogawara, Ph.D., Yoshihisa Nojima, M.D., Hirokazu Murakami, M.D.

Blood (2007) 110 (11): 2111.

https://doi.org/10.1182/blood.V110.11.2111.2111

Published: 2007

Journal Articles

Dapsone as Second-Line Drug in Non-Splenectomized Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Highly Cost Effective Option in a Developing Country.

Ajay Sharma, MD, Velu Nair, MD, Satya R. Das, MD, D.K. Mishra, MD, J. Kotwal, MD, Mohan B. Agarwal, MD

Blood (2006) 108 (11): 1073.

https://doi.org/10.1182/blood.V108.11.1073.1073

Published: 2006

Journal Articles

Anti-D Immunglobulin in the Treatment of Childhood Chronic Idiopathic Thrombocytopenic Purpura.

Emine Turkkan, MD, Fugen Pekun, MD

Blood (2006) 108 (11): 3967.

https://doi.org/10.1182/blood.V108.11.3967.3967

Published: 2006

NARROW

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Partial Splenic Embolization For The Treatment Of Steroid-Resistant Chronic Idiopathic Thrombocytopenic Purpura

Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

The Role of Helicobacter Pylori in Japanese Children with Chronic Idiopathic Thrombocytopenic Purpura

Inadequately Regulated Adrenal Steroids through HPA Axis In Chronic Idiopathic Thrombocytopenic Purpura

Patients Are Willing to Trade off Efficacy, Safety, and Administration Attributes of Chronic Idiopathic Purpura (ITP) Therapy: Results from a Large North American Discrete Choice Study

Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)

Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study

Oral Eltrombopag Treatment Reduces the Need for Concomitant Medications in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

The Influence of Polymorphisms of Interleukin-17F Genes on the Susceptibility and Clinical Significanse of Chronic Idiopathic Thrombocytopenic Purpura.

Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study.

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura.

Profiles of Th1, Th2, Th17 and Treg Cells in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

Safety of Eltrombopag, an Oral Non-Peptide Platelet Growth Factor, in the Treatment of Thrombocytopenia: Results of Four Randomized, Placebo-Controlled Studies

Prevalence Estimates of Adult Chronic Idiopathic Thrombocytopenic Purpura (ITP) in the United States.

Interleukin-10 Gene Polymorphism Reflects the Severity of Chronic Idiopathic Thrombocytopenic Purpura.

Dapsone as Second-Line Drug in Non-Splenectomized Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Highly Cost Effective Option in a Developing Country.

Anti-D Immunglobulin in the Treatment of Childhood Chronic Idiopathic Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only